Coherus BioSciences (CHRS) announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President, SVP, and Global Controller for Merck (MRK), was appointed to its Board of Directors effective May 31, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
- Coherus Biosciences presents preliminary Phase I results of CHS-114
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
- Coherus Biosciences price target raised to $12 from $11 at H.C. Wainwright